BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

Company profile
Ticker
BDX, BDXB
Exchange
Website
CEO
Thomas Polen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Baxter International • Boston Scientific • Stryker • 3M • Teleflex • Resmed • West Pharmaceutical Services • Haemonetics • Hill-Rom • Nuvasive ...
SEC CIK
Corporate docs
Subsidiaries
Accuri Cytometers, Inc. • Adaptec Medical Devices LLC • Alverix, Inc. • Bard Access Systems, Inc. • Bard Acquisition Sub, Inc. • Bard ASDI, Inc. • Bard Brachytherapy, Inc. • Bard Devices, Inc. • Bard Global Holdings I LLC • Bard Global Holdings II LLC ...
IRS number
220760120
BDX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
10 Mar 23
8-K
Entry into a Material Definitive Agreement
13 Feb 23
424B2
Prospectus for primary offering
8 Feb 23
424B2
Prospectus for primary offering
8 Feb 23
8-K
Other Events
7 Feb 23
FWP
Free writing prospectus
6 Feb 23
FWP
Free writing prospectus
6 Feb 23
424B2
Prospectus for primary offering
6 Feb 23
424B2
Prospectus for primary offering
6 Feb 23
10-Q
2023 Q1
Quarterly report
2 Feb 23
Transcripts
BDX
Earnings call transcript
2023 Q1
2 Feb 23
BDX
Earnings call transcript
2022 Q4
10 Nov 22
BDX
Earnings call transcript
2022 Q3
4 Aug 22
BDX
Earnings call transcript
2022 Q2
5 May 22
BDX
Earnings call transcript
2022 Q1
3 Feb 22
BDX
Earnings call transcript
2021 Q4
4 Nov 21
BDX
Earnings call transcript
2021 Q3
5 Aug 21
BDX
Earnings call transcript
2021 Q2
6 May 21
BDX
Earnings call transcript
2021 Q1
4 Feb 21
BDX
Earnings call transcript
2020 Q4
5 Nov 20
Latest ownership filings
4
Antoine C Ezell
6 Mar 23
4
Thomas J Spoerel
3 Mar 23
4
Michael David Garrison
3 Mar 23
4
Antoine C Ezell
3 Mar 23
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 23
3
Michelle Quinn
9 Feb 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
SC 13G/A
BlackRock Inc.
7 Feb 23
4
Richard Byrd
6 Feb 23
4
Christopher Ian Montague Jones
2 Feb 23
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 22 | Sep 21 | Sep 20 | Sep 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 744.00 mm | 744.00 mm | 744.00 mm | 744.00 mm | 744.00 mm | 744.00 mm |
Cash burn (monthly) | 138.33 mm | 108.58 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 411.59 mm | 323.08 mm | n/a | n/a | n/a | n/a |
Cash remaining | 332.41 mm | 420.92 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 2.4 | 3.9 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2022
86.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1502 |
Opened positions | 159 |
Closed positions | 117 |
Increased positions | 511 |
Reduced positions | 568 |
13F shares | Current |
---|---|
Total value | 62.64 tn |
Total shares | 246.28 mm |
Total puts | 1.46 mm |
Total calls | 1.50 mm |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 25.42 mm | $6.46 tn |
BLK Blackrock | 22.51 mm | $5.72 tn |
T. Rowe Price | 18.18 mm | $4.61 tn |
STT State Street | 12.90 mm | $3.28 tn |
Wellington Management | 10.01 mm | $2.55 tn |
MS Morgan Stanley | 8.55 mm | $2.18 tn |
Geode Capital Management | 4.94 mm | $1.26 tn |
Massachusetts Financial Services | 4.47 mm | $1.14 tn |
WFC Wells Fargo & Co. | 3.80 mm | $966.72 bn |
IVZ Invesco | 3.72 mm | $946.20 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Mar 23 | Antoine C Ezell | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 650 | 0.00 | 7,187 |
1 Mar 23 | Michael David Garrison | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 193 | 0.00 | 6,457 |
1 Mar 23 | Antoine C Ezell | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 418 | 0.00 | 7,837 |
1 Mar 23 | Thomas J Spoerel | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 35 | 0.00 | 1,874 |
3 Feb 23 | Richard Byrd | Common Stock | Sell | Dispose S | No | Yes | 248.6 | 1,421 | 353.26 k | 4,119 |
News
Becton, Dickinson's Debt Overview
10 Mar 23
(BDX) - Analyzing Becton, Dickinson's Short Interest
9 Mar 23
Becton Dickinson Reports Cybersecurity Vulnerabilities For Alaris Infusion Monitoring Software
17 Feb 23
BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test
8 Feb 23
Looking Into Becton's Return On Capital Employed
3 Feb 23
Press releases
BD Receives FDA 510(k) Clearance for First-of-Its-Kind High-Throughput Diagnostic Test for Infectious Vaginitis
16 Mar 23
BD to Present at Barclays Global Healthcare Conference
1 Mar 23
Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?
1 Mar 23
BD to Present at Cowen 43rd Annual Healthcare Conference
21 Feb 23
BD Onclarity™ HPV Assay Receives FDA Approval for Use with Both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test
21 Feb 23